Twenty-one point six percent weight loss in early responders sounds like a headline win, but the more strategically loaded number from OASIS 4 is 28.8% — the share of participants who qualified as early responders at all. Nearly three-quarters of patients on oral semaglutide 25 mg did not hit the ≥10% weight-loss threshold by week 16, yet still went on to lose 11.5% of body weight by week 64. That is a clinically meaningful outcome, and it reframes the early-response question from a patient-selection filter into a dose-titration and expectation-management instrument. Physicians now have empirical grounds to counsel slower losers to stay on therapy rather than abandon it.
The physical function data from the same trial deserve more attention than they are getting. Among participants with poor baseline physical function — people who struggled to bend, stand, or sustain activity — 77.3% achieved clinically meaningful improvements in function scores versus 42.9% on placebo. That near-doubling holds even after controlling for the fact that this subgroup lost comparable weight to the overall cohort, suggesting the functional benefit is not entirely mediated by weight reduction alone. Disentangling the direct versus weight-mediated effects of GLP-1 agonism on musculoskeletal and mobility outcomes is an endpoint design problem that future trials in this class need to solve explicitly.
Novo Nordisk also presented the ORION indirect treatment comparison against orforglipron, which found approximately 14 times higher odds of GI-related discontinuation for the Eli Lilly candidate. Indirect comparisons carry the methodological baggage they always carry — different trial populations, different titration schedules, non-identical endpoints — and presenting them at a congress without head-to-head data is a competitive maneuver as much as a scientific contribution. The 84% patient preference figure from the OPTIC survey compounds the issue: preference studies built around one compound’s profile are not neutral instruments. Regulators will not touch any of this. Payers might.
The single outcome worth tracking as oral semaglutide moves toward EMA approval is how health technology assessment bodies weight the 77.3% physical function responder rate in populations with obesity-related mobility impairment. If that endpoint anchors a distinct patient subgroup claim, it changes the reimbursement argument for the pill formulation entirely — not just relative to the injection, but relative to every oral competitor entering this market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
